Specifically, a key set of BTK mutations was identified in 9 out of 55 patients with CLL refractory to Pirtobrutinib including V416L, A428D, M437R, T474I, and L528W [77]. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.